Tocagen (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The brokerage currently has a $4.25 target price on the stock. Zacks Investment Research‘s price objective points to a potential upside of 382.95% from the company’s current price.
According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “
A number of other analysts have also weighed in on the company. Robert W. Baird reiterated a “neutral” rating on shares of Tocagen in a research note on Thursday. ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Leerink Swann set a $5.00 price target on Tocagen and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. HC Wainwright downgraded Tocagen from a “buy” rating to a “neutral” rating and set a $3.32 price target on the stock. in a research report on Thursday. Finally, Cantor Fitzgerald downgraded Tocagen from an “overweight” rating to a “neutral” rating in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.95.
Tocagen (NASDAQ:TOCA) last released its earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.04. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. As a group, analysts forecast that Tocagen will post -2.67 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of TOCA. Sphera Funds Management LTD. bought a new position in shares of Tocagen during the 1st quarter worth $1,304,000. Rubric Capital Management LP bought a new position in shares of Tocagen during the 1st quarter worth $1,176,000. GSA Capital Partners LLP bought a new position in shares of Tocagen during the 2nd quarter worth $551,000. JPMorgan Chase & Co. grew its position in shares of Tocagen by 19.0% during the 1st quarter. JPMorgan Chase & Co. now owns 453,391 shares of the company’s stock worth $4,929,000 after buying an additional 72,539 shares in the last quarter. Finally, LPL Financial LLC bought a new stake in Tocagen during the second quarter valued at about $384,000. 35.43% of the stock is currently owned by institutional investors and hedge funds.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Recommended Story: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.